🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

COVAX cuts N.Korea's COVID vaccine allotment after no deliveries accepted

Published 10/02/2022, 07:24
Updated 10/02/2022, 07:31
© Reuters. FILE PHOTO: A woman walks past a TV broadcasting file footage for a news report on North Korea firing an unidentified projectile, in Seoul, South Korea, March 9, 2020.    REUTERS/Heo Ran/File Photo

By Josh Smith

SEOUL (Reuters) - The COVAX global COVID-19 vaccine-sharing programme has scaled back the number of doses allocated for North Korea, international aid organisations said, as the country has so far failed to arrange for any shipments.

A website dashboard maintained by the United Nations children's agency, UNICEF, shows the number of doses earmarked for North Korea now stands at 1.54 million, down from as many as 8.11 million last year.

This year, COVAX is moving to needs-based vaccine allocations, so the accumulation of previously allocated doses to North Korea is no longer relevant, said a spokesperson for Gavi, the charity that helps operate the vaccine sharing programme.

"Vaccines were allocated to (North Korea) on technical considerations to enable the country to catch up with international immunization targets in 2022 in case the government decides to introduce COVID-19 immunisations as part of the national pandemic response," the spokesperson said in a statement to Reuters on Thursday.

North Korea is not known to have imported any COVID-19 vaccines, though media reports have suggested at least some key people, such as border control officials, may have been vaccinated.

Last year North Korea rejected planned shipments of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine that were being organised under COVAX due to concerns over side effects, a South Korean think-tank said at the time.

Pyongyang also turned down an offer of 3 million COVID-19 vaccine doses of China's Sinovac Biotech, UNICEF said last year.

"Gavi and COVAX are continuing the dialogue with (North Korea) to operationalize the COVID-19 immunization program," the Gavi spokesperson said.

North Korea has not officially confirmed a single coronavirus infection, though officials in South Korea and the United States have cast doubts on that the country is COVID-free.

It was one of the first countries to close its borders as the pandemic began to spread in 2020, and only last month began to allow a few trains across its border with China.

© Reuters. FILE PHOTO: A woman walks past a TV broadcasting file footage for a news report on North Korea firing an unidentified projectile, in Seoul, South Korea, March 9, 2020.    REUTERS/Heo Ran/File Photo

North Korea's parliament approved a 33.3% increase in spending to tackle the pandemic this year, state media reported on Tuesday.

"The emergency epidemic prevention work will be made the top priority of the state affairs and the epidemic prevention walls will be further intensified," premier Kim Tok Hun said in a speech.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.